In the present study, we developed an immunoassay targeting the C-terminal domain of the α-chain 1 of type IX collagen (PRO-C9) in serum and evaluated the biomarker potential in a cohort of patients with various types of cancer by comparing PRO-C9 levels across tumor types and relative to healthy controls. This evidence concerns the gene C9 and neoplasm.